Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complet if Known	
Application Number	Int'l App.: PCT/US99/25692
Filing Date	Int'l App. Filed: 2 Nov 1999
First Named Inventor	CHIEN, KENNETH et al
Group Art Unit	UNKNOWN
Examiner Name	UNKNOWN
Attorney Docket Number	6627-PA9025

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
PAD	1	5,652,122		FRANKEL, et al.	07-29-1997	
PAD	2	5,968,959		HAIKALA, et al.	10-19-1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
PAD	3		WO 97/37224	A1	MEDICAL RESEARCH COUNCIL	10-09-1997		
PAD	4		WO 99/04636	A1	THE GENERAL HOSPITAL CORP.	02-04-1999		
PAD	5		WO 99/30696	A1	ORION CORPORATION	06-24-1999		
N/A Considered LD English	~~6~~		~~FR 2,753,722~~	~~A1~~	~~SMITHKLINE BEECHAM LAB.~~	~~03-27-1998~~		

Examiner Signature	PATRICIA A DUFFY	Date Considered	6/1/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → [+]

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complet if Known	
Application Number	Int'l App.: PCT/US99/25692
Filing Date	Int'l App. Filed: 2 Nov 1999
First Named Inventor	CHIEN, KENNETH et al
Group Art Unit	UNKNOWN
Examiner Name	UNKNOWN
Attorney Docket Number	6627-PA9025

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
PAD	7	DILLMANN, Wolfgang H., Influences of Increased Expression of the Ca2+ ATPase of the Sarcoplasmic Reticulum by a Transgenic Approach on Cardiac Contractility, Ann. New York Acad Sci., 1998, 853:43-48.	
PAD	8	KOSS, Kimberly L. and KRANIAS, Evangelia G., Phospholamban: A Prominent Regulator of Myocardial Contractility, Circ Res, 79:1059-63.	
PAD	9	HE, Huaping, et al., Influence of an Antisense Phospholmaban Trasncribed By An Adenoviral Vector on Ca2+ ATPase in Cardiac Myocytes, J. Mol. Cell. Cardiol., 1997, 29:A181.	
PAD	10	HE, Huaping, et al., Effects of Mutant and Antisense RNA of Phospholamban on SR Ca2+ -ATPase Activity and Cardiac Myocyte Contractility, Circulation, 1999, 100:974-80.	
PAD.	11	MINAMISAWA, Susumu, et al., Chronic Phospholamban-Sarcoplasmic Reticulum Calcium ATPase Interaction Is the Critical Calcium Cycling Defect in Dilated Cardiomyopathy, Cell, 1999, 99:313-22.	
PAD	12	TADA, Michihiko and TOYOFUKU, Toshihiko, Molecular Regulation of Phospholamban Function and Expression, TCM, 1998, 8:330-40.	
PAD	13	TOYOFKU, Toshihiko, et al., Amino Acids Glu2 to Ile18 in the Cytoplasmic Domain of Phospholamban Are Essential for Functional Association with the Ca2+ -ATPase of Sarcoplasmic Reticulum, The Journal of Biological Chemistry, 1994, 269:3088-94.	

Examiner Signature	PATRICIA A DUFFY	Date Considered	6/1/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.